180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Readystate Asset Management LP

Readystate Asset Management LP acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 180,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,084,000. Readystate Asset Management LP owned 0.42% of KalVista Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vestal Point Capital LP raised its position in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares during the last quarter. Great Point Partners LLC acquired a new position in shares of KalVista Pharmaceuticals during the second quarter valued at approximately $15,768,000. Emerald Advisers LLC lifted its position in shares of KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after acquiring an additional 192,091 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 3,314 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after acquiring an additional 944 shares during the last quarter.

KalVista Pharmaceuticals Stock Down 2.8 %

Shares of KALV opened at $9.46 on Thursday. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.39 and a 52-week high of $16.88. The stock has a fifty day simple moving average of $10.97 and a two-hundred day simple moving average of $11.85. The company has a market capitalization of $408.81 million, a PE ratio of -2.68 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. As a group, equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KALV has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at $2,468,697.48. This represents a 5.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,016 shares of company stock worth $319,344 in the last 90 days. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).